Potential breakthrough treatment for Stargardt disease enters phase II trials
Macular Society - 08-Dec-2021Remofuscin is a promising drug to slow down or prevent vision loss in patients
Join the club for FREE to access the whole archive and other member benefits.
Ophthalmologist and Professor at University of Southampton
Andrew Lotery is an ophthalmologist at University Hospital Southampton, with a sub-specialty interest in medical retinal conditions such as age related macular degeneration and inherited retinal diseases. He joined the NHS Foundation Trust in September 2002. Previously, he worked for four years at the University of Iowa Hospitals and Clinics. He is a professor of ophthalmology at University of Southampton. He's a senior investigator for the National Institute for Health Research and chairman of the Royal College of Ophthalmologists’ scientific committee. He specializes in treating patients with inherited retinal diseases, diabetic retinopathy and age related macular degeneration.
Lotery's research interests include investigating the molecular basis of ophthalmic diseases such as macular degeneration. He also leads a research team which studies the genetics of eye diseases, and is working to develop new therapies for eye diseases with stem cells and retinal cell transplantation.
Lotery completed Medicine and MD in molecular genetics from Queen's University Belfast. He served as an assistant professor at University of Iowa.
Visit website: https://www.uhs.nhs.uk/for-patients/find-your-consultant/professor-andrew-lotery
See also: University of Southampton - Public research university for UK and international students
Details last updated 07-Jul-2023
One of the UK’s most innovative healthcare providers and a pioneer in medical research
Remofuscin is a promising drug to slow down or prevent vision loss in patients